HSTO Histogen Inc

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function as well as a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases. Under our biologics technology platform, our product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. In addition, within our small molecule pipeline, our product candidates include emricasan, CTS-2090 and CTS-2096. Currently, emricasan is being developed jointly with our collaboration partner, Amerimmune, for the treatment of COVID-19, and we are evaluating the use of emricasan for other infectious diseases including the treatment of MRSA. We also have preclinical product candidates, CTS-2090 and CTS-2096, novel, potent, orally bioavailable, and highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. For more information, please visit .

CONTACT:

Susan A. Knudson

Executive Vice President & CFO

Histogen Inc.



EN
27/07/2022

Underlying

HSTOHistogen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Histogen Inc

 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-...

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11”) in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders. ...

April 18, 2024 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Second Adjournment of Special Meeting of Stockholde...

Histogen Announces Second Adjournment of Special Meeting of Stockholders Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO), today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange C...

December 14, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Adjournment of Special Meeting of Stockholders

Histogen Announces Adjournment of Special Meeting of Stockholders Meeting Adjourned to December 14, 2023 at 8:00 a.m. PT SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 18, 2023 (the “Proxy Statement”). The reconvened Special Meeting on December 14, 2023 will...

December 5, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen Announces Board Approval of Complete Liquidation and Dissolut...

Histogen Announces Board Approval of Complete Liquidation and Dissolution SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of D...

September 18, 2023 1 EN
 PRESS RELEASE
Free
HSTO HISTOGEN INC

Histogen to Explore Strategic Alternatives

Histogen to Explore Strategic Alternatives SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternat...

July 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch